

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



8

17

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁵ : A61K 9/00, 9/22, 9/50 A61K 35/00, 48/00, A61F 2/00 A61F 2/02, A61K 37/00, 37/02 C12N 5/00, 5/06, 5/08 C12N 5/16</p>	<p>A1</p>	<p>(11) International Publication Number: WO 94/03154</p> <p>(43) International Publication Date: 17 February 1994 (17.02.94)</p>
<p>(21) International Application Number: PCT/US93/07076</p> <p>(22) International Filing Date: 28 July 1993 (28.07.93)</p> <p>(30) Priority data: 07/922,111 29 July 1992 (29.07.92) US</p> <p>(71) Applicant: WASHINGTON UNIVERSITY [US/US]; Department of Surgery, 4939 Audubon Street, St. Louis, MO 63110 (US).</p> <p>(72) Inventors: DIONNE, Keith, E. ; 35 Fairfield Street, Rehoboth, MA 02769 (US). SCHARP, David, W. ; 1129 Dunston Drive, St. Louis, MO 63146 (US).</p>	<p>(74) Agents: BREZNER, David, J. et al.; Flehr, Hohbach, Test, Albritton & Herbert, 4 Embarcadero Center, Suite 3400, San Francisco, CA 94111-4187 (US).</p> <p>(81) Designated States: AU, CA, FI, JP, KR, NO, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published With international search report.</p>	
<p>(54) Title: USE OF POUCH FOR IMPLANTATION OF LIVING CELLS</p> <p>(57) Abstract</p> <p>A device and method of use are provided for improving the long-term treatment of a patient by surgically implanting encapsulated or unencapsulated cells or cell clusters producing a therapeutic agent and for retrieving such cell bodies. A pouch is placed over a vascularized tissue pedicle in an individual's body so that at least part of the pedicle is encased by projecting into the opening of the pouch. The pouch is attached to the pedicle around the pouch opening.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

USE OF POUCH FOR IMPLANTATION OF LIVING CELLS

Background of the Invention

Therapeutic agents have been implanted into patients for treatment of chronic conditions, deficiencies and disease. In one form of treatment, microcapsules containing cells (or cell clusters) for producing such therapeutic agents, have been used. Specifically, pancreatic islet cell grafts have been performed by implantation either freely into the peritoneal cavity or into an epiploic flap pedicle. (Cugnenc, P.H., et al., Chirurgie 1990, 116(6) p.268-74, and Altman, J.J., Horm. Metab. Res. Suppl. 1990, 25 p.136-7.) Microcapsules containing other cells have been implanted in various areas of the body. One problem with known techniques is that there is no effective way to retrieve the encapsulated cells. In certain instances, it would be desirable to replace such cell capsules because of (a) possible expiration or failure of the cells, (b) a need to change the therapeutic approach or modify the dosage levels, (c) catastrophic failure, or (d) allergic reaction. When using microcapsules, a large number (e.g. hundreds or thousands) are normally employed for dispersion within the individual thereby effectively preventing retrieval.

Another approach which has been suggested is the loading of tissue fragments of insulinomas in permselective tubular membranes which are implanted. (Altman, J.J., Diabetes June 1986, 35(6) p.625-33.) Altman reports

that the insulinoma tissue retrieved after implantation showed functionally active endocrine cells and no evidence of graft rejection. However, this is not the optimum environment for long term grafts because the cells are not in close proximity to well-vascularized tissue. Also, the unencapsulated cells do not have optimal diffusional characteristics.

In view of the foregoing, there is a need for implantation of encapsulated or unencapsulated cells into a patent providing optimum conditions for long term cell viability and which permits the complete retrieval of such cells.

Summary of the Invention

In accordance with the invention, a device and method of use are provided for improving the long-term treatment of a patient by surgically implanting encapsulated or unencapsulated cells or cell clusters producing a therapeutic agent (collectively "cell bodies") and for retrieving such cell bodies. According to the method, a pouch is placed over a vascularized tissue pedicle in an individual's body so that at least part of the pedicle is encased by projecting into the opening of the pouch. The pouch is attached to the pedicle around the pouch opening.

Generally, the amount of cell bodies considered to produce a therapeutically useful amount of secretagogue will depend on systemic requirements and bioactivity of the substance. For insulin secretion, as many as 400,000 cell bodies may be required. In any event, a number of such cell bodies are dispersed onto spaced-apart locations of the pedicle within the pouch. In one technique, the pouch is placed over the pedicle, and the

cells are thereafter dispersed onto the pedicle (a) through a syringe which is moved to a number of positions along the pedicle, (b) into the pedicle tissue by the same method, (c) through a cannulated artery, or
5 some other way. Alternatively, spaced cell bodies are dispersed on and adhered to the inner wall of the pouch prior to placing the pouch over the pedicle. In this instance, the pouch is sufficiently close fitting to the pedicle so as to place the cells closely adjacent to the
10 pedicle.

Another aspect of the invention is the retrieval of the cell bodies in the pouch after conclusion of their useful life. In one retrieval technique, the pedicle is surgically removed from the patient along with the
15 pouch and contained cells. Alternatively, the cell bodies are dislodged from the pedicle, as by washing, and collected in the pouch which is removed.

The invention also includes a biocompatible and biostable flexible pouch. A number of spaced cell
20 bodies producing therapeutic agent are adhered to the inner pouch walls for transfer to the pedicle.

Brief Description of the Drawings

Figure 1 is a schematic representation of cell bodies being positioned by a syringe into a pouch encasing a
25 pedicle with the pouch in cross-section.

Figure 2 is a schematic cross-sectional view of a system for positioning cell bodies through a pedicle artery with the pouch removed.

Detailed Description of the Preferred Embodiments

Various aspects of the invention include implanting cell bodies into a tissue pedicle and retrieval of the cell bodies on termination of their useful life or for some other reason. The pouch is surgically attached to a vascularized tissue pedicle in an individual so that at least part of the pedicle is encased by projecting into the opening of the pouch. The cells may be dispersed onto the pedicle surface or into the pedicle itself by a number of techniques described below. At the desired time, the cell bodies are retrieved in the pouch, with or without the tissue pedicle, depending, in part, on the dispersion method chosen.

As used herein, the term "cell bodies" comprise encapsulated or unencapsulated living cells producing a therapeutic agent. The cells may be in any form, including but not limited to cells retained in tissue, cell clusters (e.g. islets), individually isolated cells, and natural and genetically engineered cell lines. Techniques for isolating the cells or tissues which produce therapeutic agents are known to those skilled in the art. For example, islets of Langerhans can be isolated from a large-animal pancreas (e.g. human or porcine) using a combination of mechanical distension and collagenase digestion, as described by Scharp, D.W. et al., (1989) in U.S. Patent No. 4,868,121.

A large body of literature is available directed to the formation of microcapsules containing living cells. Such microcapsules should be formed of any suitable material which allows passages of the therapeutic agents through pores or voids of a predetermined range of sizes but which protects the cells from potentially harmful large molecules (e.g. antibodies) entering the microcapsules. Suitable microspheres are of a size from

about 15 μ m to 600 μ m. They may have a capsule wall formed of alginate-polylysine-alginate configuration (e.g. as disclosed in Lim U.S. Pat. 4,352,883) or thermoplastic materials of suitable porosity, (e.g. PAN/PVC) as disclosed in Sefton U.S. Pat. 4,353,999 or Aebischer et al WO 91/10425). Macrocapsules, (e.g. sizes of about 50-100 μ m diameter and 1 to 30 mm long cylinders) may also be used.

The cell bodies of the present invention can be encapsulated or unencapsulated. However, in view of the mode of delivery of the cell bodies described below, it is preferable to encapsulate if the cell bodies are fragile. Also, encapsulation is useful to avoid immune rejection, particularly if such rejection is not readily avoided in some other way.

The term "pouch" is intended to encompass any structure (preferably flexible) which includes an opening which may be slid over the free distal end of a vascularized tissue pedicle and which is substantially enclosed except for the pouch opening. In this manner, once the pouch is attached at its opening to the pedicle, the cell bodies are retained in a region closely adjacent to the pedicle inside the pouch.

The pouch may have sufficient porosity to permit passage of therapeutic agent produced by the cell bodies into the individual's body cavity surrounding the tissue pedicle.

Alternatively, the pouch may be completely impermeable. Then, the therapeutic agent would be taken up by passing directly into the vasculature of the pedicle.

5 The pouch is biocompatible and biostable. As used
herein, "biocompatible" means that the pouch is formed
of a material which does not cause a significant
detrimental effect on the transplanted cells or on the
10 patient during a therapeutical useful time, (e.g. a
month to a year or more). Moreover, the term means that
no specific undesirable cytotoxic or systemic effects
are caused by long-term implantation of the pouch. As
used herein, the term "biostable" refers to a pouch
15 material which can withstand the implantation
environment (i.e. contain the cell bodies) for the total
time of implantation.

15 In a preferred form, the pouch is flexible and closely
conforms to the configuration of the pedicle. As used
herein, "pedicle" refers to vascularized tissue, in a
form capable of being encased by the pouch. The pedicle
receives blood supplied by an artery and depends from
and projects into a body cavity. If no naturally
occurring pedicle projects a sufficient distance for
20 useful encasement, the pedicle may be surgically freed
from surrounding tissue. Preferably, the pedicle is not
essential to the patient's body functions, thereby
permitting its removal during retrieval of the cell
bodies. Several known naturally occurring pedicles
25 include fat pads, liver lobes, pancreatic lobes, omental
flaps or portions of them.

30 Appropriate natural vascular pedicles (or their
precursors) may be found in the peritoneal cavity. For
example, a fat pad fed by a single artery and drained
by a single vein may be used. By surgical techniques,
such a fat pad pedicle can be isolated away from
surrounding tissue so that it hangs free to form a flap

of tissue inside the cavity with its own circulation intact.

5 If no suitable natural pedicle exists, an "artificial pedicle" can be formed by detaching vascularized tissue (e.g. musculofascial tissue) from the individual's body and connecting it to a vascularized source at a selected site on the wall of a cavity (e.g. abdominal cavity) within the same individual to revascularize the tissue.

10 Another form of artificial pedicle may be formed by transplantation of autologous tissue from one part of the body to another (e.g. musculature vascularized from the leg with blood supply in the middle of the tissue). The cell bodies are placed on the tissue which is folded to wrap around and contain the cell bodies. This is
15 attached to the vasculature within the individual's body cavity (e.g. abdominal cavity) to form the pendant artificial pedicle. Transplanted pedicles in some circumstances may be syngenic or allogeneic. In these instances immunosuppression will generally be required.

20 The pouch may be formed of a continuous polymeric plastic, such as molded from a flexible sheet and sealed at its edges, or it may be woven from strands in the form of fabrics. Suitable materials of appropriate porosity may be formed from polytetrafluoroethylene
25 (Teflon) or other plastic materials such as polyolefins (e.g. polyethylene, polypropylene), and polyesters. Silicone rubber may be used as a flexible impermeable pouch material, while a biocompatible material such as titanium may be used as an inflexible, impermeable
30 material.

Also, the pouch may be formed by molding a biocompatible polymer onto the surface of the pedicle and permitting the polymer to set in the form of a continuous pouch conforming to the shape of the enclosed pedicle. This may be accomplished by multiple dipping into a solution of biocompatible polymer (e.g. a cross-linked alginate) pouch which, on setting of the solvent, conforms to the pedicle.

The pouch may also be formed from a biocompatible non-absorbable mesh (e.g. a polyolefin product sold under the trademark Marlex). Alternatively, it may be formed of a reabsorbable mesh (e.g. such as polydisulfoxane, polyglycolate, or polylactate sold under the trademark Vicryl). In this instance, as the mesh is dissolved, the bag is replaced by a continuous matrix of tissue formed by angiogenesis.

In one advantageous form of the pouch, the cell bodies are contained on the interior wall of the pouch in spaced apart distribution to be uniformly distributed along the vascularized tissue pedicle. These cells can be retained in place by a suitable biocompatible adhesive or glue such as "Pronectin F" or a viscous hydrogel material such as alginate supplied under the tradename Keltone HV by Kelco, Inc. For this embodiment, it is preferable to form the pouch of an elastic material, (e.g. silicone rubber) which stretches as the pouch is slid over the pedicle to form a close fit. This is advantageous in that it provides a good distribution of the cells along the pedicle wall.

Figure 1 illustrates one method for implanting cells in accordance with the invention. Pouch 10 is slid over the vascularized tissue pedicle 12 in a body cavity such

as the peritoneal cavity so that at least part of the pedicle is encased by projecting into opening 10a of pouch 10.

5 Then, the pouch may be attached to the pedicle at opening 10a by a variety of different techniques. In one embodiment, the pouch includes a drawstring 14 which is pulled by the surgeon to tighten the perimeter of the pouch opening around the encased pedicle. In another technique, the pouch is sutured directly to the pedicle.
10 Alternatively, the perimeter of the pouch opening is elastic and attaches by expansion to fit over the pedicle to fit by contraction into a compression fit at the pouch opening. In a further embodiment, an adhesive is applied around the inner periphery of the pouch opening which causes the pouch to adhere to the pedicle.
15 Any of these or other means for attaching the opening of the pouch to a pedicle may be employed so long as such means is capable of long-term retention of the pouch around the pedicle while retaining the cell bodies within the pouch for retrieval.
20

A number of different techniques may be used to load the capsules onto or into the pedicle. One technique would be to load the cell bodies substantially onto the outer surface of the pedicle as by injection through a tube
25 in spaced apart locations or by adherence from cell bodies layered onto the inner wall of the pouch. In other techniques, the cell bodies are loaded into the interior of the tissue of the pedicle. One technique would be to implant the particles through an artery feeding the pedicle. In another technique, the cell
30 bodies would be loaded through a needle which is inserted into spaced locations throughout the interior

of the pedicle. These techniques will be described in more detail hereinafter.

Referring again to Figure 1, a specific technique is illustrated in which cell bodies 16 are suitably injected through the attached pouch by a tube or syringe 18 which places the cell bodies in spaced apart relationship either deep within the tissue of pedicle 12, on the outer surface of the pedicle, or both. Deep penetration is advantageous because of the proximity to the life sustaining environment provided by the vascular supply carried by the artery to the pedicle.

A suitable syringe technique for loading the cell bodies into the pedicle tissue is as follows. To load the syringe, the cell bodies may be lightly centrifuged and aspirated at a dilution of about 1:20 to 1:50 (e.g. 5ml of cell bodies in 50ml media) and deposited through pliable tubing into a 50ml syringe with an 18g needle. The needle is then placed at the desired location of the pouch or pedicle (e.g. the distal end of the pedicle). The cell bodies are distributed as by slowly retracting the needle leaving the cell bodies in the needle track. This may be repeated until all cell bodies are injected.

In another embodiment, illustrated in Figure 2, the cell bodies can be introduced into the pouch by a cannulated artery. That is, the cell bodies may be delivered to various portions of the pedicle through a cannula connected to an artery which feeds the pedicle. This technique may be more difficult to control than injection through the pouch wall. It may be accomplished as follows. The cell bodies are injected from syringe 18 into artery 22 feeding pedicle 12. Conventional directional aids such as fluoroscopy may

be used to locate the appropriate artery and direct the cells. If the artery includes a branch downstream from the pedicle, the branch may be temporarily blocked as by clamp 20. At or before the location where the artery narrows to capillary projections, illustrated at the bottom of the artery 22 in Figure 2 as finger-like projections, the cell body flow terminates because the cell bodies are too large to pass further, as to vein 24. The artery fingers distribute the cell bodies throughout the pedicle.

An advantageous environment for the living cells may be provided by placing a cortex-forming substrate (e.g. a polytetrafluoroethylene fiber such as sold under the trademark Gortex) around the pedicle within the pouch. Angiogenesis may be induced in such substrate by growth factors or the like. The thus-formed substrate serves to provide a scaffolding for the cell bodies.

The cells implanted in accordance with the invention may be retained for long periods of time (e.g. from one months to a year or more).

In another mode of placing the cell bodies, the pouch is preloaded with the cell bodies dispersed on and adhered to the inner wall of the pouch. Spaced cell bodies are attached to the inner pouch wall by a biocompatible adherent substance, such as alginate, coating the pouch wall. Then, the pouch is carefully placed over the pedicle so as to retain the cell bodies in spaced-apart relationship. In this instance, the pouch is preferably form-fitting to the pedicle so that the cell bodies intimately contact the pedicle when the pouch is slid over it. On attaching the pouch to the pedicle, the system is in place for long-term

implantation without the necessity of an additional injection step.

5 One way to conveniently spread the cell bodies along the interior wall of the pouch is to coat flat sheets in a two-dimensional template of the pouch with such adherent substance and to place the cell bodies in spaced apart relationship onto the sheets. Thereafter, the two sheets can be sealed at their periphery as by heat sealing or an adhesive to form a pouch of the desired configuration.

10 The type of therapy is a major factor in determining the optimum size and porosity characteristics of the pouch as well as the technique for implantation. For example, diabetes therapy uses approximately 35-75 units of insulin per day, requiring about 400,000 islets. Based upon a 150 micron diffusional distance for an interperitoneal implant site, this translates to about 60 square inches of one diffusional surface (i.e. an impermeable pouch) or 30 square inches for two diffusional surfaces (i.e. a permeable pouch). However, a surface area of 60 square inches would require a very large pedicle. Thus, a permeable pouch is preferred for islet implantation.

25 Moreover, for transplanting a large number of cell bodies, e.g. as is typically required for islets, it is preferred to load deep into the interior of the pedicle tissue (e.g. by arterial or syringe loading). However, where only a smaller number of cells are required for the desired therapeutic dosages, surface loading may be advantageously employed.

Suitable cell bodies are engineered cells which can be used by surface loading and include human growth hormone, erythropoietin, or interleukins.

5 The pedicle size should be selected to hold the desired number of cells. For example, 400,000 islets occupy a volume of approximately 8ml. For proper pedicle viability, it is preferred that the pedicle occupy at least about ten times the volume of the cells to be injected. It is most preferred to size the pedicle to be at least 20 times the volume of injected cells. Therefore, a preferred pedicle size for diabetes therapy is on the order of 160ml or more.

15 A significant advantage of the invention is the ability to retrieve the cell bodies from the patient after implantation. This permits the flexibility of replacing the cells because of possible expiration or failure of the cells or a need to change the therapeutic approach or modify dosage levels.

20 A preferred way of retrieving the cell bodies is to surgically remove the pouch, attached pedicle, and cell bodies as a unit from the individual's body. Since the pedicle is preferably selected to be superfluous to the biological function of the individual, the pedicle may be cut in the region of attachment to the pouch to remove it along with the pouch and cell bodies. This may not require a major, open surgical procedure, but can be retrieved by laproscopic procedures currently utilized for such general surgical procedures.

30 Cell bodies may also be retrieved leaving the pedicle in place. In this instance, the cell bodies are first dislodged from the pedicle and then collected in the

pouch. One technique is to wash down the pedicle by a tubing inserted through a surgical incision to cause the cell bodies to flow into the pouch. Thereafter, the pouch and contained dislodged cell bodies are removed from the individual's body leaving the pedicle in place. One problem with this approach is that some of the cell bodies may become lodged in the pedicle and not removed by washing. Thus, this technique is preferably used if retention of some cells would not cause a harmful reaction.

To more clearly illustrate the invention, the following example of its practice are set forth. It is understood that this is not intended to delineate the scope of the claims.

Example 1

Pouch contained implantation and
retrieval of microsphere encapsulate
NIT cells from a vascular pedicle

The peritoneal cavity of a rat was opened with a midline incision. A fat pad (1cm x 3cm x 0.5cm ~ 1.5ml) from the greater mesentery omentum of a sprague Dawley rat was dissected free from connective tissue and fascia with its circulation remaining intact to that it was in the form of a free floating flap. The flap remained attached to the omentum wall only at the base such that it could be easily removed. The pedicle was then inserted into a loose fitting pouch formed of nylon mesh (sold under the Nitex trademark). The pouch was held in place on the pedicle by means of a suture drawstring (#4 silk) around the pouch opening.

as the
pedicle
pouch 10

WO 94/03154

-11-

5 Then, the
opening
one embod
is pulled
pouch op
technique
10 Alternati
elastic
pedicle to
the pouch
is applic
15 opening wh
Any of the
of the po
such mean
pouch arou
20 within the

A number of
capsules of
be to load
surface of
25 in spaced
bodies lay
other techn
interior of
would be to
30 feeding the
bodies wou
inserted in

5 be used to locate the appropriate artery a
cells. If the artery includes a branch do
the pedicle, the branch may be temporari
by clamp 20. At or before the location wh
narrows to capillary projections, illus
5 bottom of the artery 22 in Figure 2 a
projections, the cell body flow terminat
cell bodies are too large to pass furthe
24. The artery fingers distribute th
10 throughout the pedicle.

15 An advantageous environment for the livin
provided by placing a cortex-forming sub
polytetrafluoroethylene fiber such as
trademark Gortex) around the pedicle wit
Angiogenesis may be induced in such subs
factors or the like. The thus-formed s
to provide a scaffolding for the cell

20 The cells implanted in accordance with the
be retained for long periods of time
months to a year or more).

25 In another mode of placing the cell bo
is preloaded with the cell bodies d
adhered to the inner wall of the pouc
bodies are attached to the inner f
biocompatible adherent substance, su
coating the pouch wall. Then, the po
placed over the pedicle so as to retai
in spaced-apart relationship. In th
pouch is preferably form-fitting to th
the cell bodies intimately contact the
30 pouch is slid over it. On attaching
pedicle, the system is in plac

WHAT IS CLAIMED IS:

1. A method for implanting into an individual a plurality of cell bodies producing a therapeutic agent, said method comprising the steps of:
 - 5 (a) placing a biocompatible and biostable pouch over a vascularized tissue pedicle pendant from and projecting into a cavity of an individual's body so that at least part of said pedicle is encased by projecting into the opening of the pouch,
 - 10 (b) attaching said pouch to said pedicle, and
 - (c) dispersing a number of said cell bodies, spaced apart, into multiple locations of said pedicle.
2. The method of Claim 1 in which said cell bodies are encapsulated.
- 15 3. The method of Claim 1 in which said placing step is performed by molding a biocompatible polymer onto the surface of said pedicle and permitting said polymer to set in the form of a continuous pouch conforming to the shape of the adjacent pedicle.
- 20 4. The method of Claim 1 in which said attaching step is performed by suturing.
5. The method of Claim 1 in which said attaching step is performed by tightening the perimeter of the pouch opening around the pedicle.
- 25 6. The method of Claim 6 in which the perimeter of said pouch opening is elastic and attaches by expansion to fit over said pedicle followed by contraction into a compression fit.

be used to locate the appropriate artery and direct the cells. If the artery includes a branch downstream from the pedicle, the branch may be temporarily blocked as by clamp 20. At or before the location where the artery narrows to capillary projections, illustrated at the bottom of the artery 22 in Figure 2 as finger-like projections, the cell body flow terminates because the cell bodies are too large to pass further, as to vein 24. The artery fingers distribute the cell bodies throughout the pedicle.

An advantageous environment for the living cells may be provided by placing a cortex-forming substrate (e.g. polytetrafluoroethylene fiber such as sold under the trademark Gortex) around the pedicle within the pouch. Angiogenesis may be induced in such substrate by growth factors or the like. The thus-formed substrate serves to provide a scaffolding for the cell bodies.

The cells implanted in accordance with the invention may be retained for long periods of time (e.g. from one month to a year or more).

In another mode of placing the cell bodies, the pouch is preloaded with the cell bodies dispersed on a substrate adhered to the inner wall of the pouch. Spaced cell bodies are attached to the inner pouch wall by a biocompatible adherent substance, such as alginate, coating the pouch wall. Then, the pouch is carefully placed over the pedicle so as to retain the cell bodies in a spaced-apart relationship. In this instance, the pouch is preferably form-fitting to the pedicle so that the cell bodies intimately contact the pedicle when the pouch is slid over it. On attaching the pouch to the pedicle, the system is in place for long-term use.

(d) placing a cortex-forming substrate around said pedicle, and

(e) inducing angiogenesis in said cortex-forming substrate.

5 15. A method for implanting into an individual a plurality of cell bodies producing a therapeutic agent, said method comprising the steps of:

10 (a) placing a biocompatible and biostable pouch over a vascularized tissue pedicle pendant from and projecting into a cavity of an individual's body so that at least part of said pedicle is encased by projecting into the opening of the pouch, said pouch containing cell bodies dispersed on and adhered to the inner wall of the pouch, and

15 (b) attaching said pouch to said pedicle.

16. The method of claim 15 in which said cell bodies are encapsulated.

17. The method of Claim 15 further comprising:

20 (d) surgically removing said pouch, attached pedicle, and cell bodies as a unit from the individual's body.

18. The method of Claim 15 further comprising:

25 (d) dislodging most of said cell bodies from said pedicle and collecting them in the pouch, and

(e) removing said pouch and contained dislodged cell or cell cluster bodies from the individual's body leaving the pedicle in place.

30 19. A device for implanting into an individual a plurality of cell bodies producing a therapeutic agent comprising a biocompatible and biostable flexible pouch

and a plurality of cell bodies producing a therapeutic agent and contained by said pouch.



20. The device of Claim 19 in which said cell bodies are encapsulated.

5 21. The device of Claim 19 in which cell bodies are dispersed on the inner wall of said pouch and adhered to the same.

10 22. The device of Claim 19 including means for attaching the opening of the pouch to a vascularized tissue pedicle.

15 23. The device of claim 19 in combination with a vascularized tissue pedicle surgically removed from an individual's body, said removed pedicle being encased by projecting into the opening of the pouch, said pouch being attached to said pedicle, said cell bodies being dispersed on multiple locations of said pedicle.

20 24. An individual implanted with cell bodies producing a therapeutic agent, comprising a biocompatible and biostable flexible pouch disposed over a vascularized tissue pedicle pendant form and projecting into a cavity of an individual's body so that at least part of said pedicle is encased by projecting into the opening of the pouch, said pouch being attached at its opening to said pedicle, and a plurality of said cell bodies dispersed
25 on multiple locations of said pedicle.



SUBSTITUTE SHEET

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : Please See Extra Sheet

US CL : Please See Extra Sheet

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S.: 424/93A, 93B, 93R, 423, 424, 425, 426, 455, 486; 435/240.2, 240.22; 604/891.1; 800/2 :

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE, USA, Volume 86, issued October 1989, Thompson et al., "Heparin-binding growth factor 1 induces the formation of organoid neovascular structures in vivo", pages 7928-7932, see entire document.	1-24
Y,P	US, A, 5,158,881 (AEBISCHER ET AL.) 27 OCTOBER 1992, see entire document.	1-24
Y	DIABETES, Volume 35, No. 6, issued June 1986, Altman et al., "Long-term plasma glucose normalization in experimental diabetic rats with macroencapsulated implants of benign human insulinomas", Abstract only, see entire document.	1-24

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A		document defining the general state of the art which is not considered to be part of particular relevance
* E	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* L	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* O		document referring to an oral disclosure, use, exhibition or other means
* P	* Z	document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
18 October 1993	02 NOV 1993

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

BRIAN R. STANTON

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*



A. CLASSIFICATION OF SUBJECT MATTER:

IPC (5):

A61K 9/00, 9/22, 9/50, 35/00, 48/00; A61F 2/00, 2/02; A61K 37/00, 37/02; C12N 5/00, 5/06, 5/08, 5/16

A. CLASSIFICATION OF SUBJECT MATTER:

US CL : 424/93A, 93B, 93R, 423, 424, 425, 426, 455, 486; 435/240.2, 240.22; 604/891.1; 800/2

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

STN-Medline, Embase; APS-USPAT

Search Terms: Membran?; permeabl; gene (w) therapy; vivo; cell#; pedic?; pendant?; pouch?; biostable; biocompatible; encapsulat?; graft?; organoid#; Dione? (AU); Sharp? (AU)

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,079,160 (LACY ET AL.) 07 JANUARY 1992, see entire document.	1-24
Y,P	US, A, 5,169,390 (ATHAYDE ET AL.) 08 DECEMBER 1992, see entire document.	1-24
Y	US, A, 4,718,894 (LAZORTHES) 12 JANUARY 1988, see entire document.	1-24
Y	US, A, 5,081,161 (OSTAPCHENKO) 14 JANUARY 1992, see entire document.	1-24